LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing syste… Read more
Market Cap & Net Worth: LivaNova PLC (LIVN)
LivaNova PLC (NASDAQ:LIVN) has a market capitalization of $3.43 Billion ($3.43 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3790 globally and #2433 in its home market, demonstrating a 1.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LivaNova PLC's stock price $62.82 by its total outstanding shares 54605527 (54.61 Million).
LivaNova PLC Market Cap History: 2015 to 2026
LivaNova PLC's market capitalization history from 2015 to 2026. Data shows change from $3.24 Billion to $3.43 Billion (-1.02% CAGR).
Index Memberships
LivaNova PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.15% | #93 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.01% | #465 of 3165 |
|
S&P Midcap 400
MID
|
$3.02 Trillion | 0.07% | #334 of 401 |
Weight: LivaNova PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LivaNova PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LivaNova PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.02x
LivaNova PLC's market cap is 2.02 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
39.99x
LivaNova PLC's market cap is 39.99 times its annual earnings
1.94x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.24 Billion | $291.56 Million | $57.85 Million | 11.12x | 56.04x |
| 2016 | $2.46 Billion | $1.21 Billion | -$62.80 Million | 2.02x | N/A |
| 2017 | $4.36 Billion | $1.01 Billion | -$25.10 Million | 4.31x | N/A |
| 2018 | $4.99 Billion | $1.11 Billion | -$189.40 Million | 4.51x | N/A |
| 2019 | $4.12 Billion | $1.08 Billion | -$157.64 Million | 3.80x | N/A |
| 2020 | $3.62 Billion | $934.24 Million | -$348.82 Million | 3.87x | N/A |
| 2021 | $4.77 Billion | $1.04 Billion | -$135.82 Million | 4.61x | N/A |
| 2022 | $3.03 Billion | $1.02 Billion | -$86.25 Million | 2.97x | N/A |
| 2023 | $2.83 Billion | $1.15 Billion | $17.55 Million | 2.45x | 161.02x |
| 2024 | $2.53 Billion | $1.25 Billion | $63.23 Million | 2.02x | 39.99x |
Competitor Companies of LIVN by Market Capitalization
Companies near LivaNova PLC in the global market cap rankings as of March 19, 2026.
Key companies related to LivaNova PLC by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
LivaNova PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, LivaNova PLC's market cap moved from $3.24 Billion to $ 3.43 Billion, with a yearly change of -1.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.43 Billion | +2.10% |
| 2025 | $3.36 Billion | +32.87% |
| 2024 | $2.53 Billion | -10.49% |
| 2023 | $2.83 Billion | -6.84% |
| 2022 | $3.03 Billion | -36.47% |
| 2021 | $4.77 Billion | +32.05% |
| 2020 | $3.62 Billion | -12.22% |
| 2019 | $4.12 Billion | -17.54% |
| 2018 | $4.99 Billion | +14.45% |
| 2017 | $4.36 Billion | +77.72% |
| 2016 | $2.46 Billion | -24.25% |
| 2015 | $3.24 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of LivaNova PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.43 Billion USD |
| MoneyControl | $3.43 Billion USD |
| MarketWatch | $3.43 Billion USD |
| marketcap.company | $3.43 Billion USD |
| Reuters | $3.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.